1. Baseline risk of hematologic malignancy at initiation of frontline PARP inhibitor maintenance for BRCA1/2-associated ovarian cancer
- Author
-
Anastasia Navitski, Duaa H. Al-Rawi, Ying Liu, Maria M. Rubinstein, Claire F. Friedman, Raajit K. Rampal, Diana L. Mandelker, Karen Cadoo, and Roisin E. O'Cearbhaill
- Subjects
Ovarian cancer ,BRCA mutation ,PARP inhibitors ,Myelodysplastic syndrome ,Acute myeloid leukemia ,Gynecology and obstetrics ,RG1-991 ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Poly(ADP-ribose) polymerase inhibitors (PARPi) are FDA approved as frontline maintenance for BRCA-associated advanced stage high-grade ovarian cancer (HGOC), having demonstrated an unprecedented improvement in relapse-free survival. Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) are rare toxicities of PARPi. We describe three patients with germline BRCA-associated (gBRCA+) HGOC and alterations in AML driver genes. Although none evidenced overt hematologic malignancy, PARPi maintenance was cautiously considered given the potential risk of MDS/AML. A better understanding of the role of clonal hematopoiesis in the subsequent development of PARPi-associated MDS/AML will improve management of this patient population.
- Published
- 2021
- Full Text
- View/download PDF